Lorlatinib (PF-06463922) NEW

Price	$8	$3	$1
Package	1KG	25KG	100KG

Min. Order:	1KG
Supply Ability:	g-kg-tons, free sample is available
Update Time:	2024-03-29

Product Details

Product Name: Lorlatinib (PF-06463922)	CAS No.: 1454846-35-5
Min. Order: 1KG	Purity: 99%
Supply Ability: g-kg-tons, free sample is available	Release date: 2024/03/29
Lead time: In stock, ready for shipment	IIn stock, r: bag/bottle/drum/IBC
bag/bottle: By express, by air, by sea	Origin: Manufacturer, advantage product
COA, MS: Available, contact us for details	NAME: Sun

1. Materials information

Name	pf-06463922
Synonym	More Synonyms

Description	Lorlatinib is a potent, dual ALK/ROS1 inhibitor, with Kis of 0.02 nM, 0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK-L1196M, respectively.
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> ALK Research Areas >> Cancer
Target	Ki: < 0.02 nM (ROS1), < 0.07 nM (ALK WT), 0.7 nM (ALK L1196M)
In Vitro	Lorlatinib demonstrates significant cell activity against ALK and a large set of ALK clinical mutations with IC50 ranging from 0.2 nM-77 nM[1]. Lorlatinib significantly inhibits cell proliferation and induces cell apoptosis in the HCC78 human NSCLC cells harboring SLC34A2-ROS1 fusions and the BaF3-CD74-ROS1 cells expressing human CD74-ROS1[2]. Lorlatinib also shows potent growth inhibitory activity and induces apoptosis in the NSCLC cells harboring either non-mutant ALK or mutant ALK fusions[3].
In Vivo	In rats, Lorlatinib displays low plasma clearance, a moderate volume of distribution, a reasonable half-life, low propensity for p-glycoprotein 1-mediated efflux and a bioavailability of 100%[1]. In vivo, Lorlatinib shows cytoreductive antitumor efficacy in the NIH3T3 xenograft models expressing human CD74-ROS1 and Fig-ROS1 via inhibition in ROS1 phosphorylation and the downstream signaling molecules, as well as inhibition of the cell cycle protein Cyclin D1 in tumors[2]. In vivo, Lorlatinib also demonstrates marked antitumor activity in mice bearing tumor xenografts expressing EML4-ALK, EML4-ALK-L1196M, EML4-ALK-G1269A, EML4-ALK-G1202R or NPM-ALK[3].
Kinase Assay	Recombinant human wild-type and mutant ALK kinase domain proteins (amino acids 1093–1411) are produced in-house using baculoviral expression, preactivated via autophosphorylation with MgATP, and assayed for kinase activity using a microfluidic mobility shift assay. The reactions contained 1.3 nM wild-type ALK or 0.5 nM mutant ALK (appropriate to produce 15-20% phosphorylation of peptide substrate after 1 h of reaction), 3 μM 5-FAM-KKSRGDYMTMQIG-CONH2), 5 mM MgCl2, and the Km level of ATP in 25 mM Hepes, pH 7.1. The inhibitors are shown to be ATP-competitive from kinetic and crystallographic studies. The Ki values are calculated by fitting the conversion (%) to a competitive inhibition equation. ROS1 enzyme is assayed as described above for ALK, except using 0.25 nM recombinant human ROS1 catalytic domain (amino acids 1883-2347). Kinase inhibitor selectivity is evaluated using a 206-kinase panel.
Cell Assay	Cells are seeded in 96-well plates in growth medium containing 10% FBS and are cultured overnight at 37°C. The following day, serial dilutions of Lorlatinib or appropriate controls are added to the designated wells, and cells are incubated at 37°C for 72 h. A CellTiter-Glo assay is performed to determine the relative cell numbers. IC50 values are calculated by concentration-response curve fitting using a four-parameter analytical method.
Animal Admin	De novoGBM tumorigenesis is initiated in LSL-FIG-ROS1;Cdkn2a?/?;LSL-Luc mice through intracranial stereotactic injections of Adeno-Cre as described previously. Tumor development is monitored using BLI as described below. Once tumors reach a given size (107 p-1·s-1·cm-2·sr-1), animals are randomLy enrolled into vehicle control or 3-, 7-, or 14-d treatment with the indicated doses of Lorlatinib. Drug is administered through s.c. implanted Alzet osmotic pumps. After treatment, mice are killed, GBM tumors are microdissected, and tissues are flash-frozen in liquid N2. The remaining brains are processed for histology.
References	[1]. Johnson TW, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinas [2]. Zou HY, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8 [3]. Zou HY, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8.

Density	1.4±0.1 g/cm3
Boiling Point	675.0±55.0 °C at 760 mmHg
Molecular Formula	C₂₁H₁₉FN₆O₂
Molecular Weight	406.413
Flash Point	362.1±31.5 °C
Exact Mass	406.155365
PSA	110.06000
LogP	1.24
Vapour Pressure	0.0±2.1 mmHg at 25°C
Index of Refraction	1.687
Storage condition	-20℃

RIDADR	NONH for all modes of transport

UNII:OSP71S83EU

(R)-26-amino-55-fluoro-11,4,7-trimethyl-6-oxo-11H-3-oxa-7-aza-2(3,5)-pyridina-1(4,3)-pyrazola-5(1,2)-benzenacyclooctaphane-15-carbonitrile

2H-8,4-Methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-

(16R)-19-Amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetraazatetracyclo[16.3.1.0.0]docosa-1(22),2,5,10,12,14,18,20-octaene-3-carbonitrile

lorlatinib

(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8- methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile

PF06463922

PF-06463922

2. Packaging of materials

For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.
For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product.

Or smaller package 1kg/bottle, 10kgs/bottle as request.

Article illustration

3. Shipping & Delivery

By Express

Provide door to door service

Suitable for goods under 50kg

Delivery: 3-7 days

Cost: low cost

Article illustration

By Air

Provide airport to airport service

Suitable for goods over 50kg

Delivery: 3-14 days

Cost: high cost

Article illustration

By Sea

Provide seaport to seaport service

Suitable for goods over 100kg

Delivery: 2-45 days

Cost: low cost

Article illustration

4. Contact information

For more details, pls contact us freely.

Email address: Sun@fdachem.com

Mob: 86 13526505137

WhatsApp/Skype/Wechat/LINE: 86 13526505137

Company Profile Introduction

Henan Fengda Chemical Co., Ltd. is located in the High-tech Development Zone of Henan Province. Specializing in the production and sales of various fine chemical products required for industrial production, including chemical raw materials, organic raw materials, petrochemicals, chemical reagents, solvents, catalysts, and additives, etc.

Recommended supplier

Product name	Price		Suppliers	Update time
Lorlatinib	$35.00/2mg	VIP5Y	TargetMol Chemicals Inc.	2024-11-08
Lorlatinib	$0.00/1g	VIP1Y	BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.	2024-08-02
Lorlatinib	$0.00/1kg	VIP1Y	Nanjing Fred Technology Co., Ltd	2023-12-29
lorlatinib	$20.00/10g		Hebei Brisk New Material Technology Co. , Ltd.	2023-05-31
lorlatinib	$200.00/1kg		Hebei Mingeng Biotechnology Co., Ltd	2022-11-28
Lorlatinib	$50.00/1KG		Qiuxian Baitai New Material Co., LTD	2021-11-04
Lorlatinib	$15.00/1KG		Zhuozhou Wenxi import and Export Co., Ltd	2021-07-10
Lorlatinib (PF-06463922)	$100.00/1ASSAYS		Handan Tongyi New Material Technology Co., Ltd	2021-03-08
Lorlatinib	$1.00/1BOU/Drum		HONG KONG IPURE BIOLOGY CO.,LIMITED	2020-11-24
PF06463922(Lorlatinib)	$2.00/1KG		Hebei Xibaijie Biotechnology Co., Ltd.	2020-07-08